SCHEMBL4049480

SCHEMBL4049480

COc1ccccc1-c1cnc2nc(-c3cccc(C(F)(F)F)c3)[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.46
PDE5A O76074 2/20 0.46
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
THRB P10828 1/20 0.45
CYP2C9 P11712 1/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
STAT6 P42226 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4053263 0.92 PDE5A (0.52) AURKAPDE5APTPN5SCN2APDGFRB
SCHEMBL4058101 0.87 AURKA (0.50) AURKAPDE5ACYP3A4PDGFRBPDGFRA
SCHEMBL13608583 0.83 PDGFRB (0.46) KDM4EMEN1NPC1ALDH1A1CYP1A2
SCHEMBL4057030 0.83 SCN2A (0.53) AURKAKDM4EMEN1NPC1ALDH1A1
SCHEMBL4053763 0.83 AURKA (0.56) AURKAPDE5APDGFRBPDGFRA
SCHEMBL4050873 0.83 AURKA (0.58) AURKAKDM4EMEN1NPC1ALDH1A1
SCHEMBL4054400 0.82 AURKA (0.52) AURKAPDE5AKDM4ENPC1RAB9A
SCHEMBL4058832 0.81 AURKA (0.46) AURKAPDE5AMEN1ALDH1A1CYP1A2
SCHEMBL4058461 0.81 SCN2A (0.56) AURKAKDM4EMEN1NPC1ALDH1A1
SCHEMBL4059872 0.81 AURKA (0.61) AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885PDE5A 2762/4885KDM4E 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.